Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Castle Biosciences Q3 2026 Results: Net Loss of $4.1M, Loss Widens

Castle Biosciences reported net revenues of $102.9 million for the third quarter of 2026, up from $83.0 million in 2025. Despite the revenue growth, the company realized a net loss of $4.1 million for the quarter, primarily driven by increased operating expenses in selling, general, and administrative functions.

Watch the Castle Biosciences Inc earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue102.983.0
Net income-4.1-0.5
EPS (diluted, $ a share)$-0.13$-0.02

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+23.9%
Operating margin-2.7%
Source

10-Q filed with the SEC, NASDAQ: CSTL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Castle Biosciences Inc: key numbers

Share price
$32.75Close, Nov 16
Market cap
$1.01B
Shares outstanding
30.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Castle Biosciences Inc

All →
4:06 PM ET Form 4
Insider Selling

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $112K of Stock

Tobin W. Juvenal, Chief Commercial Officer, sold 3,195 shares of Castle Biosciences Inc at $35.07 a share, worth $112K in total on Nov 11, 2026. Shares held after the trade: 32,737 (-8.9%).

Value
$112K
Shares
3,195
Price
$35.07
Role
Chief Commercial Officer
Holding change
-8.9%
Trade date
Nov 11, 2026
4:13 PM ET Form 4
Insider Selling

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $207K of Stock

Tobin W. Juvenal, Chief Commercial Officer, sold 6,116 shares of Castle Biosciences Inc at $32.67 to $35.04 a share (average $33.77) in 2 transactions, worth $207K in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 32,737 (-8.0%).

Value
$207K
Shares
6,116
Average price
$33.77
Role
Chief Commercial Officer
Holding change
-8.0%
Trade date
Nov 9, 2026 to Nov 11, 2026
4:11 PM ET 8-K
Financial Results

Castle Biosciences Financial Results

Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.

Term
Q3 2026

“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”

Derek Maetzold, president and chief executive officer of Castle Biosciences
4:08 PM ET Form 4
Insider Selling

Castle Biosciences Pres. & Chief Exec. Officer Derek J. Maetzold Sells $523K of Stock

Derek J. Maetzold, Pres. & Chief Exec. Officer, sold 14,496 shares of Castle Biosciences Inc at $36.01 to $36.81 a share (average $36.10) in 6 transactions, worth $523K in total on Nov 2, 2026. Shares held after the trade: 1,396 (-18.9%).

Value
$523K
Shares
14,496
Average price
$36.10
Role
Pres. & Chief Exec. Officer
Holding change
-18.9%
Trade date
Nov 2, 2026
4:06 PM ET Form 4
Insider Selling

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $240K of Stock

Tobin W. Juvenal, Chief Commercial Officer, sold 6,578 shares of Castle Biosciences Inc at $35.58 to $36.62 a share (average $36.42) in 2 transactions, worth $240K in total on Oct 28, 2026. Shares held after the trade: 38,853 (-12.1%).

Value
$240K
Shares
6,578
Average price
$36.42
Role
Chief Commercial Officer
Holding change
-12.1%
Trade date
Oct 28, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.